SCHEMBL2580862

SCHEMBL2580862

CCOP(=O)(OCC)C(Cl)C#N

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
TP53 P04637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ACHE P22303 1/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.35
GAA P10253 2/20 0.33
PPARD Q03181 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
MAPT P10636 2/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL124930 0.76 TSHR (0.42) TSHRTP53TDP1ACHECYP3A4
SCHEMBL22455362 0.76 TSHR (0.42) TSHRTP53TDP1ACHECYP3A4
SCHEMBL6546035 0.75 ACHE (0.38) TSHRTP53TDP1ACHECYP3A4
SCHEMBL9342999 0.74 TSHR (0.41) TSHRTP53TDP1ACHECYP3A4
SCHEMBL6527556 0.74 TSHR (0.41) TSHRTP53TDP1ACHECYP3A4
SCHEMBL23774976 0.74 TSHR (0.41) TSHRTP53TDP1ACHECYP3A4
SCHEMBL5105445 0.74 TSHR (0.46) TSHRTP53TDP1ACHECYP3A4
SCHEMBL25519711 0.74 TSHR (0.41) TSHRTP53TDP1ACHECYP3A4
SCHEMBL2458189 0.74 TP53 (0.50) TSHRTP53TDP1CYP3A4CYP2C9
SCHEMBL7066106 0.74 TP53 (0.50) TSHRTP53TDP1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391695-B2 PRMT5 inhibitors LUPIN LIMITED (IN) 2025-08-19 US disclosed
WO-2024074611-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2024-04-11 WO disclosed
EP-3980417-B1 PRMT5 INHIBITORS LUPIN LTD (IN) 2023-09-27 EP disclosed
US-20230159510-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2023-05-25 US disclosed
US-20230159510-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2023-05-25 US disclosed
EP-4103558-A1 NOVEL PRMT5 INHIBITORS Amgen Inc. (US) 2022-12-21 EP disclosed
US-20220315589-A1 PRMT5 INHIBITORS LUPIN LIMITED (IN) 2022-10-06 US disclosed
EP-3980417-A1 PRMT5 INHIBITORS Lupin Limited (IN) 2022-04-13 EP disclosed
US-9605004-B2 Chemical compounds SYNGENTA LIMITED (GB) 2017-03-28 US disclosed
US-9605004-B2 Chemical compounds SYNGENTA LIMITED (GB) 2017-03-28 US disclosed
US-20160159819-A1 CHEMICAL COMPOUNDS SYNGENTA LIMITED (GB) 2016-06-09 US disclosed
US-20160159819-A1 CHEMICAL COMPOUNDS SYNGENTA LIMITED (GB) 2016-06-09 US disclosed
WO-2015018434-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-02-12 WO disclosed
WO-2015018433-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-02-12 WO disclosed
WO-2015018434-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-02-12 WO disclosed
WO-2015018433-A1 PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2015-02-12 WO disclosed
EP-2114871-B1 A CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND AND ITS USE IN PEST CONTROL SUMITOMO CHEMICAL CO (JP) 2014-07-30 EP disclosed
EP-2114871-B1 A CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND AND ITS USE IN PEST CONTROL SUMITOMO CHEMICAL CO (JP) 2014-07-30 EP disclosed
US-8048916-B2 Ester compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-11-01 US disclosed
US-20100041750-A1 Ester Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041750-A1 Ester Compound and Use Thereof CYP51A1, NOTUM, CYP46A1 TSHR 4400/4885TP53 4781/4885TDP1 3681/4885
US-20220315589-A1 PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 TSHR 2698/4885TP53 1627/4885TDP1 246/4885
US-12391695-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 TSHR 2698/4885TP53 1627/4885TDP1 246/4885
US-20160159819-A1 CHEMICAL COMPOUNDS RDX, CBR3, RRS1 TSHR 633/4885TP53 2064/4885TDP1 1376/4885
US-20230159510-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 TSHR 2615/4885TP53 1988/4885TDP1 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.